Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Evolution of taxanes in the treatment of metastatic breast cancer.

Binder S.

Clin J Oncol Nurs. 2013 Feb;17 Suppl:9-14. doi: 10.1188/13.CJON.S1.9-14. Review.

2.

Metastatic breast cancer epidemiology and management with a focus on taxanes.

Donovan D.

Clin J Oncol Nurs. 2013 Feb;17 Suppl:5-8. doi: 10.1188/13.CJON.S1.5-8.

3.

Taxanes as a first-line systemic treatment in metastatic breast cancer.

Urquhart LM.

Clin J Oncol Nurs. 2013 Feb;17 Suppl:15-21. doi: 10.1188/13.CJON.S1.15-21.

4.

An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.

Benedict A, Cameron DA, Corson H, Jones SE.

Pharmacoeconomics. 2009;27(10):847-59. doi: 10.2165/10899510-000000000-00000.

PMID:
19803539
5.

Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.

Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.

Health Technol Assess. 2007 Oct;11(40):1-144. Review.

6.

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.

Dranitsaris G, Coleman R, Gradishar W.

Breast Cancer Res Treat. 2010 Feb;119(3):717-24. doi: 10.1007/s10549-009-0424-z. Epub 2009 Jun 3.

PMID:
19495958
7.

Paclitaxel and docetaxel in the treatment of breast cancer.

Saloustros E, Mavroudis D, Georgoulias V.

Expert Opin Pharmacother. 2008 Oct;9(15):2603-16. doi: 10.1517/14656566.9.15.2603 . Review.

PMID:
18803448
8.

Use and abuse of taxanes in the management of metastatic breast cancer.

Bernard-Marty C, Cardoso F, Piccart MJ.

Eur J Cancer. 2003 Sep;39(14):1978-89. Review.

PMID:
12957452
9.

The role of taxanes in the treatment of breast cancer.

Nabholtz JM, Gligorov J.

Expert Opin Pharmacother. 2005 Jun;6(7):1073-94. Review.

PMID:
15957963
10.

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.

Dranitsaris G, Cottrell W, Spirovski B, Hopkins S.

J Oncol Pharm Pract. 2009 Jun;15(2):67-78. doi: 10.1177/1078155208098584. Epub 2008 Nov 26.

PMID:
19036903
11.

Taxanes in the treatment of early breast cancer.

Ring AE, Ellis PA.

Cancer Treat Rev. 2005 Dec;31(8):618-27. Epub 2005 Nov 2. Review.

PMID:
16266787
12.

[Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands].

Nortier JW.

Ned Tijdschr Geneeskd. 2004 Jul 31;148(31):1524-8. Dutch.

PMID:
15366720
13.

Taxanes: impact on breast cancer therapy.

Bachegowda LS, Makower DF, Sparano JA.

Anticancer Drugs. 2014 May;25(5):512-21. doi: 10.1097/CAD.0000000000000090.

PMID:
24552749
14.

Advances in the use of taxanes in the adjuvant therapy of breast cancer.

Nabholtz JM, Vannetzel JM, Llory JF, Bouffette P.

Clin Breast Cancer. 2003 Aug;4(3):187-92. Review.

PMID:
14499011
15.

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.

Petrelli F, Borgonovo K, Barni S.

Expert Opin Pharmacother. 2010 Jun;11(8):1413-32. doi: 10.1517/14656561003796562. Review.

PMID:
20446855
16.

Special considerations in the management of older adult patients with metastatic breast cancer.

Donovan D.

Clin J Oncol Nurs. 2013 Feb;17 Suppl:41-8. doi: 10.1188/13.CJON.S1.41-48.

17.

Taxanes in the treatment of breast cancer: a prodigy comes of age.

Miller KD, Sledge GW Jr.

Cancer Invest. 1999;17(2):121-36. Review.

PMID:
10071597
18.

Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.

Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains JP, Paridaens R.

Crit Rev Oncol Hematol. 2010 Jul;75(1):70-7. doi: 10.1016/j.critrevonc.2009.07.001. Epub 2009 Aug 3.

PMID:
19651523
19.

Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.

Sachdev JC, Jahanzeb M.

Clin Breast Cancer. 2016 Apr;16(2):73-81. doi: 10.1016/j.clbc.2015.09.007. Epub 2015 Sep 25. Review.

PMID:
26603443
20.

Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.

Schwartzberg LS, Cobb P, Walker MS, Stepanski EJ, Houts AC.

Support Care Cancer. 2009 Aug;17(8):1081-8. doi: 10.1007/s00520-008-0558-2. Epub 2009 Jan 13.

PMID:
19148686

Supplemental Content

Support Center